1. Market Research
  2. > Healthcare
  3. > Pathology Market Trends
Sexually Transmitted Diseases  Drug Market  - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2017 - 2025

Sexually Transmitted Diseases Drug Industry: Forecasts to 2025

  • November 2017
  • 293 pages
  • ID: 5233177
In this report:
According to the World Health Organization (WHO), vaccination has reduced the global burden of infectious disease to a great extent.
Table ##: Incidence rates (per ##,##) by infection and sex, based on 2005 to 2012 data (##% uncertainty interval shown in parentheses)
Table ##: Percentage of population (%) with prevalent infection in 2012 by infection and sex (##% uncertainty interval shown in parentheses)

Summary

Table of Contents

Global Sexually Transmitted Diseases Drugs: Summary

Sexually transmitted diseases, also referred as venereal diseases are infections that can pass from person to person during sex. These diseases are caused primarily due to bacteria, viruses, and / or parasites. Sexually transmitted diseases often go undiagnosed because these infections usually do not exhibit visual symptoms. Chlamydia is a frequent sexually transmitted disease. It is caused by bacteria called Chlamydia trachomatis. It can infect both men and women. Gonorrhea is caused due to bacterial infection that can be passed from one person to another during sex. The human immunodeficiency virus refers to a type of retrovirus that causes acquired immunodeficiency syndrome. HIV attacks some immune cells and causes weakness of immune system resulting in loss of ability to fight against the organism that causes disease.

Global Sexually Transmitted Diseases Drugs: Trends and Opportunities

The overall market for sexually transmitted diseases drug is expanding significantly, owing to increased chances of infection led by rise in the life expectancy of people across the world. Rise in incidences of unprotected sex has led to an increase in the prevalence of sexually transmitted diseases. A driving factor for the sexually transmitted diseases drug is growing initiatives by governments and multiple agencies drawn up guidelines or recommendations for sexually transmitted diseases. Low voluntary screening rate for sexually transmitted diseases is main restrain for this sector.

Global Sexually Transmitted Diseases Drugs: Segmentation

The overall sexually transmitted diseases drug sector has been broken down by disease type, therapy class, distribution channel, and region. On the bases of disease type, sexually transmitted diseases drug market can be farther split into chlamydia, gonorrhea, syphilis, human papillomavirus infection, HIV/AIDS and others. According to therapy class sexually transmitted diseases drug market can be divided into antibiotics, antiviral, vaccines and others. Antiviral drugs are used in the treatment of lethal viral infections caused by viruses such as human immunodeficiency virus, hepatitis, influenza A and B viruses and herpes viruses. Vaccination has been promoted as a vital public health intervention across the world for decades. According to the World Health Organization, vaccination has reduced the overall burden of infectious disease to a great extent. In terms of distribution channel, the sexually transmitted diseases drug market can be broken down into hospitals pharmacies, retail pharmacies, online pharmacies and others. In terms of income, the hospitals segment held a meaningful share of the sexually transmitted diseases drug market in 2016.

Global Sexually Transmitted Diseases Drugs: Regional Outlook

Geographically, the overall sexually transmitted diseases drug market is split into five regions: North America (NA), Europe (EU), Asia Pacific (APAC), Latin America area and Middle East (ME) & African continent. These areas have been farther divided by countries, disease type, and therapy class and distribution channel. North America continent dominated the industry and is anticipated to gain more market share by the end of 2025. The competition matrix section included in the analysis is likely to assist the existing players to increase their market shares and additional companies to establish their presence in the overall sexually transmitted diseases drug market.

Companies discussed in the report

The study also describes main actors in the segment based on several features such as corporate overview and financial analysis, SWOT study, main business strategies, product portfolio, and recent evolutions. Main companies competing in the overall sexually transmitted diseases drug market, and profiled in the market research contain Pfizer INC, Hoffmann La Roche, Bayer Healthcare, Eli Lilly, Johnson & Johnson, Bristol-Myers Squibb Co. AbbVie, Incorporated, Gilead Sciences, GlaxoSmithKline Plc, and Merck & Co., Incorporated

Sexually Transmitted Diseases Drug Market, by Geography

North America (NA)

Europe (EU)

Asia-Pac

Latin America

African region & Middle East

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 150+ Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Chlamydia Infections - Pipeline Review, H2 2018

Chlamydia Infections - Pipeline Review, H2 2018

  • $ 2000
  • September 2018

Chlamydia Infections - Pipeline Review, H2 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Chlamydia Infections - Pipeline Review, H2 2018, provides an ...

Anal Cancer - Pipeline Review, H2 2018

Anal Cancer - Pipeline Review, H2 2018

  • $ 2000
  • August 2018

Anal Cancer - Pipeline Review, H2 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Anal Cancer - Pipeline Review, H2 2018, provides an overview of the Anal ...

Gonorrhea - Pipeline Review, H2 2018

Gonorrhea - Pipeline Review, H2 2018

  • $ 2000
  • August 2018

Gonorrhea - Pipeline Review, H2 2018SummaryGlobal Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Gonorrhea - Pipeline Review, H2 2018, provides an overview of the Gonorrhea ...


ref:plp2017

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.

Make sure you don’t miss any news and follow us on